Novo Nordisk

Saxenda

Liraglutide 3.0 mg

First-generation daily GLP-1 for weight management — less weight loss than the weekly options.

Chronic Weight Management 8.0% avg weight loss

66 B−

Evidence Score

Score Breakdown

Overview

Saxenda (liraglutide 3.0 mg) is a once-daily injectable GLP-1 receptor agonist approved in 2014 for chronic weight management. As a first-generation agent, it proved the viability of GLP-1 therapy for obesity in the SCALE trial program, though newer once-weekly options produce larger mean weight loss.

Mechanism of Action

Once-daily GLP-1 receptor agonist that slows gastric emptying, promotes central satiety, and enhances glucose-dependent insulin secretion.

Clinical Evidence

The SCALE Obesity and Prediabetes trial (3,731 adults without diabetes) showed 8.0% mean weight loss at 56 weeks versus 2.6% with placebo, establishing the foundation for modern incretin-based obesity medicine.

Where Inflammation Compass Fits

Inflammation Compass is a whole-blood RNA-seq wellness test. It reports gene-activity patterns in circulating immune cells across three Health Domains — Activation, Antiviral Response and Resolution — against a nine-stage inflammatory program, and estimates immune-cell composition from the same data. It does not measure Saxenda levels, receptor activity, or metabolic pathways in the liver, fat or muscle, and it cannot tell you whether Saxenda is working. What it offers someone taking Saxenda is a repeatable view of their own immune gene-activity patterns over time, at whatever retest cadence they choose.

Side Effects & Safety

GI adverse events (nausea, vomiting, diarrhea) are the most common. In adult trials, 9.8% of patients discontinued Saxenda because of adverse reactions, versus 4.3% on placebo.

FAQ

Is Saxenda still used for weight loss?

Yes. Saxenda remains FDA-approved for adults, and for adolescents 12 and older weighing more than 60 kg with obesity. Once-weekly Wegovy and Zepbound produced larger mean weight loss in their pivotal trials (14.9% and 20.9%, versus 8.0% for Saxenda).

Quick Facts

Generic: Liraglutide 3.0 mg
Manufacturer: Novo Nordisk
Key Trial: SCALE
Score: 66/100 (B−)

Sources

Testing & Guides

Compare Others

Founding Cohort

Track Your Immune Patterns on Saxenda — Cohort Now Forming

See what your immune system is doing while you take Saxenda. Reserve your spot today to lock in founding pricing before the general public.